2,778 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by AJOVista LLC

AJOVista LLC acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,778 shares of the company’s stock, valued at approximately $99,000.

A number of other hedge funds have also modified their holdings of the business. Fisher Asset Management LLC boosted its stake in IDEAYA Biosciences by 1,609.8% during the 4th quarter. Fisher Asset Management LLC now owns 539,025 shares of the company’s stock worth $19,179,000 after purchasing an additional 507,500 shares during the period. Victory Capital Management Inc. purchased a new position in shares of IDEAYA Biosciences during the fourth quarter worth about $12,328,000. Callan Capital LLC acquired a new position in IDEAYA Biosciences in the 4th quarter valued at about $239,000. New York State Common Retirement Fund raised its stake in IDEAYA Biosciences by 98.6% during the 4th quarter. New York State Common Retirement Fund now owns 40,657 shares of the company’s stock valued at $1,447,000 after acquiring an additional 20,185 shares during the last quarter. Finally, Federated Hermes Inc. lifted its position in IDEAYA Biosciences by 14.8% during the 4th quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock worth $138,185,000 after acquiring an additional 500,046 shares during the period. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Trading Up 1.7 %

Shares of IDYA stock traded up $0.69 during mid-day trading on Friday, reaching $42.18. The stock had a trading volume of 356,005 shares, compared to its average volume of 634,283. IDEAYA Biosciences, Inc. has a 12-month low of $18.50 and a 12-month high of $47.74. The business has a 50-day simple moving average of $42.74 and a 200 day simple moving average of $37.98. The company has a market cap of $3.15 billion, a P/E ratio of -21.41 and a beta of 0.83.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, February 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. The business had revenue of $3.90 million for the quarter, compared to analyst estimates of $8.84 million. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -2.26 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IDYA. BTIG Research began coverage on IDEAYA Biosciences in a report on Friday, March 8th. They issued a “buy” rating and a $55.00 target price on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of IDEAYA Biosciences in a research note on Friday, February 23rd. Capital One Financial restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Thursday, February 22nd. Royal Bank of Canada boosted their target price on IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 21st. Finally, The Goldman Sachs Group lifted their price target on IDEAYA Biosciences from $36.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $46.60.

Insider Buying and Selling at IDEAYA Biosciences

In related news, CEO Yujiro S. Hata sold 23,557 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the sale, the chief executive officer now owns 677,887 shares of the company’s stock, valued at $30,870,973.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Yujiro S. Hata sold 23,557 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the transaction, the chief executive officer now owns 677,887 shares of the company’s stock, valued at $30,870,973.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Briseno Andres Ruiz sold 2,000 shares of IDEAYA Biosciences stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the sale, the insider now directly owns 24,531 shares of the company’s stock, valued at $1,128,916.62. The disclosure for this sale can be found here. 3.50% of the stock is owned by insiders.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.